SCYNEXIS, Inc. (SCYX): Price and Financial Metrics


SCYNEXIS, Inc. (SCYX): $5.70

-0.37 (-6.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SCYX POWR Grades


  • Value is the dimension where SCYX ranks best; there it ranks ahead of 64.23% of US stocks.
  • The strongest trend for SCYX is in Momentum, which has been heading down over the past 47 weeks.
  • SCYX's current lowest rank is in the Momentum metric (where it is better than 4.63% of US stocks).

SCYX Stock Summary

  • SCYX has a higher market value than only 15.53% of US stocks; more precisely, its current market capitalization is $137,217,842.
  • With a year-over-year growth in debt of 102.07%, Scynexis Inc's debt growth rate surpasses 91.75% of about US stocks.
  • Scynexis Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -87.33%, greater than the shareholder yield of just 2.4% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Scynexis Inc are MOSY, HSTO, APVO, KLIC, and ICCC.
  • Visit SCYX's SEC page to see the company's official filings. To visit the company's web site, go to www.scynexis.com.

SCYX Valuation Summary

  • In comparison to the median Healthcare stock, SCYX's price/sales ratio is 11.01% higher, now standing at 12.6.
  • SCYX's EV/EBIT ratio has moved up 1.3 over the prior 89 months.
  • SCYX's EV/EBIT ratio has moved up 1.3 over the prior 89 months.

Below are key valuation metrics over time for SCYX.

Stock Date P/S P/B P/E EV/EBIT
SCYX 2021-08-31 12.6 4.7 -3.4 -1.8
SCYX 2021-08-30 12.2 4.6 -3.3 -1.7
SCYX 2021-08-27 12.3 4.6 -3.3 -1.7
SCYX 2021-08-26 11.9 4.4 -3.2 -1.6
SCYX 2021-08-25 12.1 4.5 -3.2 -1.6
SCYX 2021-08-24 12.3 4.6 -3.3 -1.7

SCYX Growth Metrics

  • Its 2 year net cashflow from operations growth rate is now at -75.65%.
  • The 4 year cash and equivalents growth rate now stands at -46.01%.
  • Its 4 year net cashflow from operations growth rate is now at -57.73%.
Over the past 70 months, SCYX's revenue has gone up $3,328,000.

The table below shows SCYX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 12.05 -38.895 -44.82
2021-03-31 12.05 -36.056 -52.859
2020-12-31 0 -49.354 -55.185
2020-09-30 0 -46.24 -26.932
2020-06-30 0 -46.773 -35.782
2020-03-31 0.057 -45.675 -37.804

SCYX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SCYX has a Quality Grade of C, ranking ahead of 30.64% of graded US stocks.
  • SCYX's asset turnover comes in at 0.134 -- ranking 233rd of 677 Pharmaceutical Products stocks.
  • ACER, MNOV, and OVID are the stocks whose asset turnover ratios are most correlated with SCYX.

The table below shows SCYX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.134 1 -3.908
2021-03-31 0.169 1 -5.208
2020-12-31 0.000 NA -3.192
2020-09-30 0.000 NA -1.322
2020-06-30 0.000 NA -1.486
2020-03-31 0.001 1 -1.353

SCYX Price Target

For more insight on analysts targets of SCYX, see our SCYX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.36 Average Broker Recommendation 1.36 (Strong Buy)

SCYX Stock Price Chart Interactive Chart >

Price chart for SCYX

SCYX Price/Volume Stats

Current price $5.70 52-week high $10.25
Prev. close $6.07 52-week low $4.20
Day low $5.69 Volume 209,819
Day high $5.93 Avg. volume 522,631
50-day MA $6.60 Dividend yield N/A
200-day MA $7.56 Market Cap 132.34M

SCYNEXIS, Inc. (SCYX) Company Bio


SCYNEXIS, Inc., a pharmaceutical company, develops and commercializes novel anti-infectives to address unmet therapeutic needs. Its lead product candidate includes SCY-078, which is in Phase I clinical trials of the intravenous formulation; Phase II clinical trials for the treatment of invasive candida infections; and Phase II clinical trials for unmet medical needs, such as vulvovaginal candidiasis. The company was founded in 1999 and is based in Jersey City, New Jersey.


SCYX Latest News Stream


Event/Time News Detail
Loading, please wait...

SCYX Latest Social Stream


Loading social stream, please wait...

View Full SCYX Social Stream

Latest SCYX News From Around the Web

Below are the latest news stories about Scynexis Inc that investors may wish to consider to help them evaluate SCYX as an investment opportunity.

SCYNEXIS Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)

Submission is part of the Hansoh Pharma licensing agreement and strategic partnership to research, develop and commercialize ibrexafungerp in the Greater China regionJERSEY CITY, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) has filed an investigational new drug

Yahoo | September 13, 2021

SCYNEXIS to Participate in Upcoming Investor Conferences

JERSEY CITY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Company will participate in the following virtual investor conferences in September.

Intrado Digital Media | September 8, 2021

Antifungal Drugs Market by latest COVID-19 Impact and Global Analysis to 2027 with leading players Scynexis, Gilead Sciences, Glenmark Pharmaceutical

According to The Insight Partners market research study titled Antifungal Drugs Market to 2027 Global Analysis and Forecasts by Infection Type, Drug Type, Therapeutic Indication, Dosage Form and Geography. The global Antifungal Drugs market is expected to reach US$

OpenPR | August 31, 2021

SCYNEXIS EPS beats by $0.40

No summary available.

Seeking Alpha | August 16, 2021

SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update

JERSEY CITY, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the second quarter ended on June 30, 2021 and provided an update on recent clinical and corporate developments.

Intrado Digital Media | August 16, 2021

Read More 'SCYX' Stories Here

SCYX Price Returns

1-mo -2.90%
3-mo -21.05%
6-mo -27.85%
1-year 6.74%
3-year -54.40%
5-year -83.99%
YTD -25.49%
2020 -15.93%
2019 89.58%
2018 -79.31%
2017 -27.27%
2016 -48.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8728 seconds.